secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001193125-23-047759
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis prices $350M public offering of common stock and pre-funded warrants
----------------------------------------------------------------------------

- Offering of 3,174,603 shares at $63.00/share and pre-funded warrants for 2,380,956 shares at $62.9999/warrant.
- Total gross proceeds ~$350M; net proceeds ~$333M (or ~$383M if underwriters' option exercised).
- Underwriters granted 30-day option to purchase up to 833,333 additional shares.
- Expected closing February 27, 2023; net proceeds to fund operations into Q1 2025.
- J.P. Morgan, Goldman Sachs, and Evercore acting as joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523047759/0001193125-23-047759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523047759/d454389d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-047759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer